Sign In
Buy AXSM
$233.49
+11.33 (+5.10%)
At Close: Jun 03, 2026
Why Axsome Therapeutics Stock Rocketed Higher to End 2025
12:12pm, Wednesday, 31'st Dec 2025
Axsome just received priority review designation for its most important drug. Auvelity is an oral medication already approved for adults with major depressive disorder (MDD).
Pharma Stock Soars to Record Highs on FDA Buzz
11:32am, Wednesday, 31'st Dec 2025
Pharma stock Axsome Therapeutics Inc (NASDAQ:AXSM) is soaring to all-time highs, up 19% at $177.13 at last glance, after the U.S. Food & Drug Administration (FDA) granted priority review to AXS-05 --
FDA Fast-Tracks Axsome's Alzheimer's Agitation Drug, Stock Soars
10:30am, Wednesday, 31'st Dec 2025
On Wednesday, the U.S. Food and Drug Administration (FDA) accepted Axsome Therapeutics Inc.'s (NASDAQ: AXSM) supplemental New Drug Application (NDA) for AXS-05 (dextromethorphan HBr and bupropion HCl)
Market Movers: Nike Exploding Higher on Insider Buying
10:08am, Wednesday, 31'st Dec 2025
Oversold shares of Nike (NYSE: NKE) are on the run. All on news that CEO Elliott Hill bought 16,400 shares for about $1 million. This follows news that Apple's Tim Cook bought $3 million worth of Nike
FDA grants AXS-05 Priority Review designation and sets PDUFA action goal date of April 30, 2026 NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutica
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission
06:55am, Wednesday, 31'st Dec 2025
New Drug Application (NDA) submission on track for January 2026 NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in t
Axsome Therapeutics (NASDAQ:AXSM) Reaches New 12-Month High – Here’s Why
03:32am, Sunday, 21'st Dec 2025
Axsome Therapeutics, Inc. (NASDAQ: AXSM - Get Free Report) reached a new 52-week high during trading on Friday. The stock traded as high as $154.49 and last traded at $151.96, with a volume of 183511
Assenagon Asset Management S.A. Raises Stock Holdings in Axsome Therapeutics, Inc. $AXSM
03:24am, Friday, 19'th Dec 2025
Assenagon Asset Management S.A. increased its stake in shares of Axsome Therapeutics, Inc. (NASDAQ: AXSM) by 62.9% in the undefined quarter, according to its most recent disclosure with the Securities
Axsome Therapeutics, Inc. (AXSM) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
06:18pm, Thursday, 04'th Dec 2025
Axsome Therapeutics, Inc. (AXSM) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Axsome (AXSM) Up 5.3% Since Last Earnings Report: Can It Continue?
12:31pm, Wednesday, 03'rd Dec 2025
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?
2 Under-the-Radar Stocks to Buy Heading Into 2026
08:06pm, Monday, 01'st Dec 2025
Axsome Therapeutics boasts a deep late-stage pipeline with billions in potential revenue opportunity. Exelixis' core franchise remains strong while it develops promising new medicines.
Axsome Therapeutics to Participate in Upcoming Investor Conferences
07:00am, Thursday, 20'th Nov 2025
NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today an
Envestnet Asset Management Inc. Grows Stake in Axsome Therapeutics, Inc. $AXSM
04:58am, Sunday, 16'th Nov 2025
Envestnet Asset Management Inc. grew its stake in shares of Axsome Therapeutics, Inc. (NASDAQ: AXSM) by 12.4% in the second quarter, according to its most recent filing with the Securities and Exchang
2 Monster Stocks in the Making
04:45am, Monday, 10'th Nov 2025
Viking Therapeutics is developing innovative medicines in a fast-growing area. Axsome Therapeutics is generating strong sales, and solid regulatory progress could improve things.
Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics
07:00am, Thursday, 06'th Nov 2025
MIAMI, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (OTC: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization
